Lund Melanoma Study Group
71 – 80 of 225
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer : A prospective cohort study
(
- Contribution to journal › Article
- 2020
-
Mark
Effect of delay between nuclear medicine scanning and sentinel node biopsy on outcome in patients with cutaneous melanoma
(
- Contribution to journal › Article
-
Mark
Desloratadine and loratadine use associated with improved melanoma survival
(
- Contribution to journal › Letter
-
Mark
The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response
(
- Contribution to journal › Article
-
Mark
Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma
(
- Contribution to journal › Article
-
Mark
Long-term outcome of pT1a–b, cN0 breast cancer without axillary dissection or staging : a prospective observational study of 1543 women
(
- Contribution to journal › Article
-
Mark
Desloratadine and loratadine stand out among common H1-antihistamines for association with improved breast cancer survival
(
- Contribution to journal › Article
-
Mark
Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes
(
- Contribution to journal › Scientific review
-
Mark
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility
(
- Contribution to journal › Article
-
Mark
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
(
- Contribution to journal › Article